Janssen unveils long-term data for HIV drug Symtuza
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV.
Read More
Tag: emtricitabine
US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
Read More
Three medicines step closer to EU approval
Three medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting.
Read More
US green light for Gilead’s HIV combo
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
Read More
National PreP service would be cost effective, research finds
Providing pre-exposure prophylaxis (PrEP) treatment to men who have sex with men at high risk of contracting HIV in England would be cost-effective and could prevent 25 percent of cases of infection, according to UCL research.
Read More
Janssen’s HIV combo pill hits safety, efficacy targets
Janssen Pharmaceutica’s experimental combination therapy for HIV containing four medicines in a single pill has hit safety and efficacy targets in a late stage trial, results of which have been published in The Lancet HIV.
Read More
Eleven medicines leap closer to EU approval
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
Gilead’s new HIV therapy under EU review
European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.
Read More
Scotland first UK nation to routinely offer HIV PrEP
Scotland will become the first UK nation to routinely offer HIV pre-exposure prophylaxis to all eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada alongside four other new therapies to be funded by the NHS.
Read More
Court rules that NHS England can fund HIV PReP
The Court of Appeal has ruled that NHS England does indeed have the legal power to fund what campaigners refer to as a “game-changing” drug to prevent the transmission of HIV under a strategy called Pre-Exposure Prophylaxis (PrEP).
Read More
NICE backs efficacy of Truvada for HIV PrEP
The National Institute for Health and Care Excellence has published an evidence summary on the use of Gilead’s Truvada for HIV pre-exposure prophylaxis (PrEP) in adults at high risk of infection.
Read More
Ten medicines leap towards EU approval
Ten new medicines have taken a giant leap closer to European Union approval after having won the backing of the Committee for Medicinal Products for Human Use.
Read More
- UKHSA and ICL confirm variant which plays key role in global surge of Strep A infections
- Study reveals heart failure device could monitor patients and prevent hospitalisation
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
